Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HST-1011 Monotherapy and Combination with Cemiplimab in Advanced Solid Tumors
NCT05662397Phase 2Active, not recruiting
- Sponsor
- HotSpot Therapeutics
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of HST-1011 in solid tumor, ovarian cancer, anal cancer, rectal cancer, prostate cancer (PCa), sponsored by HotSpot Therapeutics. Started Mar 2023; status: active, not recruiting.
02
Drugs
HST-1011
03
Conditions
solid tumorovarian canceranal cancerrectal cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT05662397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662397.